| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility | Sue Sutter | 10/08/20 | Boston |
| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
| Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders | Frank Vinluan | 09/23/20 | San Diego |
| Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2 | Frank Vinluan | 09/23/20 | Europe |
| Athira CEO Kawas: Alzheimer’s Drug Aims for “Recovery of Brain Function” | Frank Vinluan | 09/23/20 | Seattle |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest | Frank Vinluan | 09/08/20 | San Francisco |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests | Frank Vinluan | 08/27/20 | Seattle |
| Alzheon Lands $47M to Take Another Shot at a Pivotal Alzheimer’s Test | Frank Vinluan | 08/20/20 | Boston |
| AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact | Frank Vinluan | 08/07/20 | Boston |
| Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds | Frank Vinluan | 08/06/20 | San Francisco |
| AbbVie Walks From Voyager R&D Pact Spanning Alzheimer’s, Parkinson’s | Frank Vinluan | 08/04/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug | Frank Vinluan | 07/29/20 | Europe |
| Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing | Sarah de Crescenzo | 07/08/20 | Boston |
| Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s | Frank Vinluan | 07/01/20 | Boston |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| Cerevance Raises $45M to Advance Brain Disease Research & Development | Sarah de Crescenzo | 04/14/20 | Boston |
| Axsome Plans to Try Again After Failure in Treatment-Resistant Depression | Frank Vinluan | 03/30/20 | New York |
| Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects | Sarah de Crescenzo | 03/05/20 | San Diego |
| Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies | Sarah de Crescenzo | 02/28/20 | National |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
